Disitamab Vedotin: A Novel HER2 ADC

Time: 9:30 am
day: Day One


– Disitamab vedotin is a HER2 ADC with an antibody designed to maximize drug delivery with higher affinity and internalization rate as compared to trastuzumab in preclinical models
– Exploring DV’s encouraging monotherapy clinical data across a range of HER2 expressing solid tumors
– Understanding how DV has demonstrated combination activity preclinically and clinically with anti-PD1